Advanced search
Start date
Betweenand
Related content
(Reference retrieved automatically from Web of Science through information on FAPESP grant and its corresponding number as mentioned in the publication by the authors.)

TOP2A copy number and TOP2A expression in uterine benign smooth muscle tumours and leiomyosarcoma

Full text
Author(s):
Baiocchi, Glauco ; Visoni Poliseli, Fernando Luis ; De Brot, Louise ; Mantoan, Henrique ; Schiavon, Beatriz Nunes ; Faloppa, Carlos Chaves ; Vassallo, Jose ; Soares, Fernando Augusto ; Cunha, Isabela Werneck
Total Authors: 9
Document type: Journal article
Source: Journal of Clinical Pathology; v. 69, n. 10, p. 884-889, OCT 2016.
Web of Science Citations: 3
Abstract

Aims To examine TOP2A copy number, TOP2A expression, and its prognostic value in uterine leiomyosarcoma (LMS) and other benign smooth muscle tumours. Methods We analysed 37 patients treated for uterine LMS with immunohistochemistry for protein expression and fluorescence in situ hybridisation (FISH) for copy number. Twelve cases of leiomyoma variants (LMVs), 4 smooth muscle tumours of uncertain malignant potential (STUMP) and 23 leiomyomas (LMs) were also included. Results Eighteen patients with LMS (48.6%) were International Federation of Gynecology and Obstetrics (FIGO) stage I, six (16.2%) were stage II, four (10.8%) were stage III, and nine (24.3%) were stage IV. Twenty-one (56.8%) patients with LMS showed high expression of TOP2A. Greater TOP2A levels were found in patients with stage II disease compared with stage I and also in high mitotic index tumours (>20/10 HPF (high power field)). Eleven (36.7%) cases had abnormal TOP2A copy numbers. There was no link between TOP2A copy number and TOP2A expression. All patients with benign smooth muscle tumours had low TOP2A immunohistochemical expression and one (7.7%) patient had TOP2A amplification. TOP2A expression and TOP2A copy number had no impact on disease outcomes. Only the presence of disease outside of the uterus negatively impacted survival compared with early disease (53.4 vs 15.8months; p<0.001). Conclusions TOP2A is highly expressed in advanced LMS but not in non-malignant diseases. TOP2A expression does not correlate with FISH results and does not predict outcome. TOP2A levels are higher in high-mitotic index tumours and in more advanced stages of disease. (AU)

FAPESP's process: 13/01489-3 - TOP2A evaluation in uterine leiomyosarcoma
Grantee:Glauco Baiocchi Neto
Support Opportunities: Regular Research Grants